List of Ponvory drug patents
Ponvory is owned by Janssen Pharms.
Ponvory contains Ponesimod.
Ponvory has a total of 5 drug patents out of which 0 drug patents have expired.
Ponvory was authorised for market use on 18 March, 2021.
Ponvory is available in tablet;oral dosage forms.
Ponvory can be used as treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose, reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Drug patent challenges can be filed against Ponvory from 2025-03-18.
The generics of Ponvory are possible to be released after 10 December, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(1 year, 7 months from now) | |
| US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(1 year, 7 months from now) | |
| US8273779 | JANSSEN PHARMS | Thiazolidin 4-one derivatives |
Dec, 2025
(2 years from now) | |
| US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 2025-03-18
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET;ORAL
PONVORY family patents
18
United States
12
European Union
8
Korea, Republic of
7
Japan
5
Israel
5
Australia
4
China
4
Canada
3
South Africa
3
Denmark
3
Mexico
3
Slovenia
3
Morocco
3
Brazil
3
Croatia
3
Portugal
3
Malaysia
3
Spain
3
Poland
3
Chile
3
Taiwan, Province of China
3
EA
2
Hong Kong
2
Russia
2
Lithuania
2
Hungary
2
Philippines
2
Norway
2
Singapore
2
Argentina
2
Cyprus
2
Ukraine
2
New Zealand
1
IB
1
Austria
1
Saudi Arabia
1
Germany
1
Netherlands
1
RS
1
United Kingdom
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic